MRI provides superior imaging for diverse clinical applications, but cost and other factors limit availability in various healthcare and lower resource settings. Low-field strength units promise to expand access but involve trade-offs including reduced signal, longer acquisitions, and uncertain benefit of contrast agents. Here we characterize T1 and T2 properties of ferumoxytol, an iron oxide agent with prolonged blood pool phase and higher R1 and R2 values than gadolinium, on a 64mT portable system. We demonstrate enhancement across a range of concentrations in phantoms and visualization of cerebral vasculature in patients receiving the agent for iron-deficiency anemia.
This abstract and the presentation materials are available to members only; a login is required.